Geographic Atrophy

Post-hoc analysis shows promising results in reducing functional vision loss with avacincaptad pegol

Findings from a post-hoc analysis from the GATHER trials presented at ARVO 2023 signaled that reduced rate of vision loss was correlated with reduced geographic atrophy (GA) growth in patients receiving avacincaptad pegol (ACP). These findings suggest that ACP may be a promising treatment option for patients with GA, regardless...